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Abstract
Background: The objective of this study was to assess the potential impact of the implementation of multiple-criteria
decision analysis (MCDA) on the Polish pricing and reimbursement (P&R) process with regard to orphan drugs.
Methods: A four step approach was designed. Firstly, a systematic literature review was conducted to select the MCDA
criteria. Secondly, a database of orphan drugs was established. Thirdly, health technology appraisals (HTA
recommendations) were categorized and an MCDA appraisal was conducted. Finally, a comparison of HTA and MCDA
outcomes was carried out. An MCDA outcome was considered positive if more than 50 % of the maximum number of
points was reached (base case). In the sensitivity analysis, 25 % and 75 % thresholds were tested as well.
Results: Out of 2242 publications, 23 full-text articles were included. The final MCDA tool consisted of ten criteria. In
total, 27 distinctive drug-indication pairs regarding 21 drugs were used for the study. Six negative and 21 positive HTA
recommendations were issued. In the base case, there were 19 positive MCDA outcomes. Of the
27 cases, there were 12 disagreements between the HTA and MCDA outcomes, the majority of which related to
positive HTA guidance for negative MCDA outcomes. All drug-indication pairs with negative HTA recommendations
were appraised positively in the MCDA framework. Economic details were available for 12 cases, of which there were 9
positive MCDA outcomes. Amongst the 12 drug-indication pairs, two were negatively appraised in the
HTA process, with positive MCDA guidance, and two were appraised in the opposite direction.
Conclusions: An MCDA approach may lead to different P&R outcomes compared to a standard HTA process. On the
one hand, enrichment of the list of decision making criteria means further scrutiny of a given health technology and as
such increases the odds of a negative P&R outcome. On the other hand, it may uncover additional values and as such
increase the odds of positive P&R outcomes.
Background
Health technology assessment (HTA) is defined as “a
multidisciplinary process that summarises information
about the medical, social, economic and ethical issues
related to the use of a health technology in a systematic,
transparent, unbiased, robust manner. Its aim is to
inform the formulation of safe, effective, health policies
that are patient focused and seek to achieve best value”
[1] In practice, a pricing and reimbursement (P&R)
process based on HTA outcomes is very often only
restricted to the review of clinical effectiveness, cost-
effectiveness and budget impact. Excluding other aspects
from the decision making framework meets with justifi-
able criticism. Having acknowledged that challenge, ex-
perts are currently pursuing new approaches that could go
beyond standard HTA forms and allow for further evalu-
ation of wider societal benefits in the decision making
process.
Culyer very explicitly advocated for abandoning the
current limitations of the HTA algorithm and searching
for new approaches that go beyond the boundaries
established by the current form of HTA analysis [2]. In
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the checklist that was developed, he identified 13 different
ethical items to be considered by the HTA framework.
Others go even further than that and suggest more
advanced solutions such as multiple-criteria decision
analysis (MCDA) [3]. In principle, this is a set of methods
and approaches to aid decision-making, where decisions
are based on multiple, often conflicting, criteria [4], and
this approach has already been widely adopted in different
areas of science and industry [5]. Discussion regarding its
applicability to the Pricing & Reimbursement process for
medicines has already been initiated as well. In addition to
the development of ISPOR Task Force guidelines, the first
examples of its adaptation to the healthcare decision
making process have started to emerge [6].
The objective of this study was to assess the impact of
the implementation of MCDA into the P&R process
with regard to rare diseases. The choice of orphan drugs
was based on the belief that trade-off between non-
economic and economic criteria is most visible there. As
far as the ethical aspects are concerned, it has to be
acknowledged that 50 % of rare diseases lead to chronic
disability and significantly reduce quality of life. The
Committee for Orphan Medicinal Products estimated
that between 2000 and 2005 as many as 40 % of health
states for which orphan medicinal products had been
authorized did not have any therapeutic alternative [7].
As far as the economic burden of disease is concerned,
prices for orphan drugs are a particularly important chal-
lenge in the P&R decision making process [8]. This is not
surprising if one takes into consideration the fact that the
median price of orphan drugs has almost doubled since
2010 and was already 19 times higher than non-orphan
products in 2014 [9].
Having acknowledged multiple challenges in the field of
rare diseases, the EU Commission has already launched a
number of projects that aim to improve patients’ access
to orphan drugs [10], including the establishment of the
Mechanism of Coordinated Access to Orphan Drugs
working group [11]. Among its key deliverables, the
Transparent Value Framework (TVF) was developed
[12]. Its objective was really to construct the list of
criteria contributing to the value of new orphan drugs
and design a framework which helps to determine how a
new medicine fulfils each of them at a given point in time.
As such, the established TVF can be considered as one of
the very first attempts towards the implementation of
MCDA in the P&R process for orphan drugs. However,
there is still limited understanding with respect to the
potential impact of MCDA adaptation on the HTA
outcomes. Therefore the objective of this study was set to
provide relevant insight with regard to this.
Central Eastern European (CEE) settings were delib-
erately chosen for the purpose of this research. As con-
flict between economic and non-economic criteria is
very feasible there, it offers a unique framework for the
assessment of MCDA from both historical and context-
ual perspectives. The available evidence suggests that
CEE societies attribute great value towards the princi-
ples of equity and moral justice [13–15]. At the same
time, the scarcity of healthcare resources prove extremely
challenging in making room for non-economic criteria in
the decision making processes.
To our knowledge, at the present time there are no
real life examples of the implementation of MCDA to
the P&R decision making process regarding rare diseases
in the CEE Region, and so it would be interesting to
verify whether the adaptation of MCDA would improve
access to orphan therapies. In particular, it is thought
provoking to ask whether the implementation of an
MCDA approach to the HTA process would have pro-
duced different outcomes from that of a standard HTA
process.
As the biggest country in the CEE region, Poland was
selected for the purpose of this study. In 2012, roughly
6,8 % of Polish GDP was spent on health care and this
was one of the smallest shares amongst OECD countries
[16]. In contrast to the jurisdiction of other CEE coun-
tries, HTA recommendations are made publicly available
by the Polish HTA Agency (AHTAPoL) which enables
such a study to be conducted. In addition to that, the
choice of Poland met the expectation of some inter-
national experts who had indicated a lack of evidence
regarding the P&R status of orphan drug technologies in
this particular setting [17].
The Polish HTA process consists of two steps [18].
Firstly, AHTAPoL’s analytical team prepares the assess-
ment of the HTA dossier submitted by the manufacturer.
Usually, it consists of clinical effectiveness, cost effective-
ness and budget impact analysis. Secondly, appraisal of
the assessment report alongside other relevant docu-
ments, including the HTA dossier is conducted by the
Consultative Council (the Appraisal Body). As a result,
either negative or positive HTA guidance is issued. The
latter can be prepared with or without restrictions and is
only a recommendation. Hence the Ministry of Health is
not compelled to follow the advice of the Appraisal Body.
To reach the objective of this study, a four step ap-
proach was taken. Firstly, an MCDA tool was devel-
oped. Secondly, a database of orphan drugs reviewed
by the AHTAPoL (dataset) was established. Thirdly, a
categorization of HTA recommendations and MCDA
appraisals was conducted. Finally, a comparison of HTA
recommendations and MCDA outcomes was carried out.
Methods
The development of and MCDA tool
Firstly a systematic literature review was conducted. Its
objective was to elicit the criteria used in the decision
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making processes regarding both pricing and reim-
bursement and the implementation of orphan drug
technology to clinical settings. A literature search was
conducted in the PubMed Database in September 2014.
The following keywords and their combinations were
adopted: orphan diseases, rare diseases, neglected dis-
eases, health technology assessment, HTA, pharmacoe-
conomics, reimbursement, cost effectiveness, evaluation
criteria, multi criteria decision analysis, MCDA. Only full
text articles written in English and concerning EU settings
were included. A grey literature search was also con-
ducted. Both research publications and non-original arti-
cles (such as summaries and reviews) were included.
Conference abstracts, supplements and comments were
excluded. No time limits were imposed.
In the first step, two independent reviewers evaluated
each publication separately and agreed on its inclusion.
Any disagreements were solved by consensus. In the
second step, both reviewers studied each publication
independently in order to elicit the evaluation criteria
used in each particular case. A comparison of elicitation
tables were produced afterwards. To avoid double count-
ing a lack of correlation with other adopted measures
was ensured. Only those which were mentioned in at
least two original articles were included. In the last step,
a final table was drawn up with the evaluation criteria
agreed by both reviewers.
Secondly, a simple MCDA linear additive model called
a “value measurement model” was constructed. It is one
of the most widely used value measurements for model-
ing approach [19]. It is based on overall values V(a) to
combine particular scores and weights brought out for
selected orphan medicinal products. The overall values
V(a) are usually obtained by aggregating the particular
value scores received for all relevant partial criteria. The
additive aggregation is formulated by the following
equation as:




V(a) overall value (OV)
ωi relative importance (weight) of the ith criterion
vi the performance value score (partial value functions)
of the ith criterion
To simplify the assessment of orphan medicinal prod-
ucts under the proposed MCDA framework it was
assumed that all relative weights are equal, so vi for all
instances has value equal to unity (vi). The rating scale for
particular value scores (vi) ranged from 0 points at the
worst outcome to 2 points at the best outcome. After the
expected performance of each medicine technology was
conducted against selected criteria, an aggregation of all
partial scores followed to indicate the overall value (OE).
Database of orphan drugs reviewed by the AHTAPoL
In the second step, HTA recommendations issued by the
AHTAPoL agency in the period 2007–2011 concerning
drug technologies with orphan indication were extracted
from the Polish HTA agency website. Each indication for
the same active substance was considered individually and
treated as a distinctive case (drug-indication pair).
HTA outcomes
HTA recommendations were grouped into positive and
negative ones. The first ones were further divided into
guidance without and with conditions. Limitations on
time or the size of population were distinguished as
restrictions, as well as the condition regarding the reduc-
tion of the cost of therapy. The negative HTA recom-
mendations were grouped either by clinical or economic
reasons for rejection. In the case of both of these being
mentioned, the HTA recommendation was classified as
negative based on clinical reason.
MCDA outcomes
The MCDA tool that was developed was utilized to
appraise each drug technology with orphan indication
evaluated by AHTAPoL. In order to establish the
required evidence as per each MCDA’s criteria, HTA
recommendations and other relevant documents pub-
lished on AHTAPoL’s website, as well as the European
Public Assessment Reports (EPARs) and Scientific Discus-
sion reports (SDRs) of the European Medicines Agency
(EMEA), were utilized. Data gaps were complemented by
support from published review papers [20]. Every drug-
indication pair was appraised by each MCDA criteria
separately and scored accordingly by two reviewers inde-
pendently. Any disagreements were solved by consensus.
Given that CEA (cost effectiveness analysis) and BIA
(budget impact analysis) results were not always revealed,
two separate appraisals using an MCDA tool without and
with economic criteria were conducted. In case CEA or
BIA results were confidential or missing, a given drug-
indication pair was utilized for MCDA appraisal without
economic criteria only.
MCDA outcome was considered positive if more than
50 % of the maximum number of points was reached.
Otherwise, a negative MCDA outcome was assumed. In
addition to 50 % (base case), two other thresholds were
chosen for the purpose of the sensitivity analysis, these
were 25 % and 75 % of the maximum number of points
respectively.
Comparison of HTA recommendations and MCDA
outcomes
In total, four different sets of comparisons were consti-
tuted, of which two had the same and two had conflicting
outcomes.
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Results
Development of an MCDA framework
A total of 2242 records were identified from the PubMed
Database. 2165 publications were excluded following title
screening. Out of the remaining 77 full-text articles, 42
did not meet the inclusion criteria. Overall 35 full-text
articles were reviewed of which only 15 reported any
criteria to be applied in the MCDA tool. Additionally eight
publications were identified from the references of the
articles initially searched. If different versions of the same
documents were published, only the latest version was
reviewed and included if relevant. The systematic litera-
ture review flow is presented in Fig. 1.
In the course of the systematic literature review, ten
and nine criteria were selected and excluded for the
MCDA tool respectively (Additional file 1: Tables S1 and
S2). The key requirement for the inclusion of any MCDA
criteria was to be mentioned in at least two publications.
The main reason for the exclusion was the overlap with
any of those already included. The key characteristics of
the studies included can be found in Additional file 1:
Table S3.
Database of orphan drug-indication pairs
In total, 27 HTA guidances with regard to orphan drug
technologies were issued in the period between 2007
and 2011 by AHTAPoL. In summary, 21 drug technolo-
gies were included in this study, which represents 26 % of
the overall number of all known orphan drug technologies
registered in the EU by the end of 2011 [21]. Out of 27
HTA recommendations, economic considerations were
only revealed in 12 cases.
HTA outcomes
Out of 27 cases related to 21 active substances, six
(22 %) received negative and 21 (78 %) received positive
recommendations (Table 1). Clinical reasons prevailed
amongst negative HTA guidance. The majority of positive
HTA recommendations were restrictive. Reimbursement
limited to a specific subpopulation of patients was recom-
mended in most occasions.
MCDA outcomes
The MCDA framework that was developed is presented
in Table 2. In the base case, there were 19 (70 %) and
nine (75 %) positive MCDA outcomes respectively with-
out and with economic criteria being included (Tables 3
and 4).
In total, the majority of points were granted to the
severity of the disease in question and the evidence of
clinical effectiveness. At the same time, the lowest scores
were assigned to the availability of alternative technology
and economic criteria if available.
In the group of drug-indication pairs above the 50 %
threshold, indication uniqueness and lack of therapeutic
alternative were scored highest. In the group of cases
below the 50 % threshold, advancement of technology
and the results of CEA and BIA, if available, received the
lowest number of points.
Irrespective of whether the ranking included or excluded
economic criteria, Elaprase and Fabrazyme received the
highest and Glivec (MDS/MPD) the lowest number of
points.
Comparison of HTA and MCDA outcomes
Agreement between HTA and MCDA outcomes
There were 12 (44 %) cases of agreement between HTA
and MCDA if economic criteria were excluded in the
base case (Tables 5 and 6). The corresponding number
was 8 (66 %) if economic criteria were included. The
majority of agreements related to positive outcomes.
There was only one example of consistency with respect
to negative recommendations. This happened when eco-
nomic criteria were taken into consideration.
Disagreement between HTA and MCDA outcomes
Positive HTA vs negative MCDA outcome In the base
case there were seven and two cases of negative MCDA
outcomes for positive HTA recommendations respect-
ively without and with economic criteria being included
(Tables 5 and 6). Amongst these disagreements, AHTA-
PoL’s unrestricted guidances prevailed and were followed
by restrictions to subpopulation in both groups. At the
same time, the lowest MCDA scores were given to the
criteria of availability of alternative treatment options,
complexity of manufacturing technology, disease rarity
and advancement of technology.
Negative HTA vs positive MCDA outcome
In the base case, there were five and two cases respectively
of negative HTA recommendation appraised positively
with the MCDA tool without and with economic criteria
being included. While insufficient clinical evidence was
raised as a key reason for a negative HTA recommenda-
tion, it was indication uniqueness, disease severity and
rarity which were scored highest in the MCDA appraisal
process.
Sensitivity analysis
25 % and 75 % thresholds were applied for MCDA ap-
praisal in the sensitivity analysis. If economic criteria
were excluded, there would only have been two drug-
indication pairs with a positive MCDA outcome for the
75 % threshold. Both of them received a negative HTA
recommendation. There would have only been negative
MCDA outcomes if economic criteria were being included
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Fig. 1 Systematic review flow. A literature search was conducted in the PubMed Database in September 2014. The following keywords and their
combinations were adopted: orphan diseases, rare diseases, neglected diseases, health technology assessment, HTA, pharmacoeconomics,
reimbursement, cost effectiveness, evaluation criteria, multi criteria decision analysis, MCDA. Only full text articles written in English and
concerning EU settings were included. A grey literature search was also conducted.
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for the 75 % threshold. At the same time all cases would
have received a positive MCDA appraisal if the 25 %
threshold was applied irrespective of whether CEA and
BIA results were to be included or excluded.
Discussion
The objective of this study was to address the question
of whether MCDA implementation in the HTA process
would have changed HTA outcomes and consequently
Table 1 HTA recommendations issued between 2007 and 2011 for orphan drug technologies by AHTAPol.
No. Brand name
(active substance)
Indication HTA guidance Reason for HTA recommendation
1 Fabrazyme
(Agalsidase beta)
Fabry disease (alpha-galactosidase A deficiency) –
long-term replace therapy
Negative Insufficient clinical effectiveness, safety concerns,
not cost-effective vs standard of care
2 Elaprase (Idursulfase) Mucopolysaccharidosis type II, MPS II (Hunter
syndrome) – long-term treatment
Negative Insufficient clinical effectiveness
3 Kuvan
(Tetrahydrobiopterin)
Hyperphenylalaninemia (HPA) in patients with
tetrahydrobiopterin (BH4) deficiency
Positive Restricted with time limits
4 Increlex (Mecasermin) Insulin-like growth factor deficiency -IGFD
(Laron Syndrome) – long-term treatment
Positive Restricted with time limits
5 Somavert (Pegvisomant) Acromegaly Negative Insufficient clinical effectiveness, not
cost-effective vs standard of care
6 Ventavis (Iloprost) Pulmonary arterial hypertension (PAH) Positive Restricted to subpopulations




9 Zavesca (Miglustat) Niemann-Pick type C syndrome (disease) Positive Restricted with time limits, conditional on the
reduction of cost of therapy
10 Volibris (Ambrisentan) Pulmonary arterial hypertension (PAH) Positive Unrestricted
11 Nexavar (Sorafenib) Renal cell carcinoma (RCC) Negative (2008) Insufficient clinical effectiveness, not
cost-effective vs standard of care, unacceptable
budget impact
12 Nexavar (Sorafenib) Renal cell carcinoma (RCC) Negative (2009) Not cost-effective vs standard of care,
unacceptable budget impact
13 Nexavar (Sorafenib) Hepatocellular carcinoma (HCC) Positive Restricted to subpopulations
14 Nplate (Romiplostim) Chronic immune (idiopathic) thrombocytopenic
purpura (ITP)
Positive Restricted to subpopulations
15 Torisel (Temsirolimus) Renal cell carcinoma (RCC) Negative Insufficient clinical effectiveness, not
cost-effective vs standard of care
16 Tasigna (Nilotinib) Chronic myeloid leukemia (CML) Positive Restricted to subpopulations, conditional on the
reduction of cost of therapy
17 Vidaza (Azacitidine) Acute myelogenous leukemia (AML) Positive Unrestricted
18 Glivec (imatinib) Philadelphia chromosome positive chronic
myeloid leukemia (ALL Ph+)
Positive Unrestricted
19 Glivec (imatinib) Myelodysplastic/myeloproliferative diseases
(MDS/MPD)
Positive Unrestricted
20 Glivec (imatinib) Dermatofibrosarcoma protuberans (DFSP) Positive Unrestricted
21 Glivec (imatinib) Malignant gastrointestinal stromal tumors (GIST) Positive Unrestricted
22 Revlimid (Lenalidomide) Multiple myeloma (MM) Positive Restricted to subpopulations
23 Revlimid (Lenalidomide) Myelodysplastic/Myeloproliferative syndrome
(MM/S) (off-label indication)
Positive Off-label indication, restricted to subpopulations,
conditional on the reduction of cost of therapy
24 Yondelis (Trabectedin) Soft tissue sarcoma Positive Restricted to subpopulations, conditional on the
reduction of cost of therapy
25 Sprycel (Dasatinib) Chronic myeloid leukemia (CML) Positive Restricted to subpopulations
26 Revatio (Sildenafil) Pulmonary arterial hypertension (PAH) Positive Unrestricted
27 Atriance (Nelarabine) T-cell acute lymphoblastic leukemia Positive Restricted to subpopulations, conditional on the
reduction of cost of therapy
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influenced the pricing and reimbursement decision mak-
ing process regarding orphan therapies in Polish settings.
In total, 27 individual drug-indication pairs were reviewed
and evaluated through an MCDA framework.
To our knowledge this was one of very few attempts
to adapt an MCDA approach to the assessment of
orphan drug technologies worldwide and the first one in
a CEE setting. Several authors have advocated for the
application of a multi-criteria decision analysis frame-
work to health technologies for rare diseases but so far
only limited research has been published. Hence our study
with a sample of as many as 27 individual cases can be
clearly distinguished from other pilot studies [22].
This research provides some interesting insights into
why the adaptation of an MCDA approach may lead to
different P&R outcomes compared to a standard HTA
process. On the one hand, the enrichment of the list of
decision making criteria means further scrutiny of the
health technology in question and as such increases the
chances of negative P&R outcomes. On the other hand
the inclusion of wider societal perspectives may uncover
additional values of a given health technology and as
such increase the chances of positive P&R outcomes.
As far as the broadening of a P&R decision making
basis is concerned, the study revealed that there were
more negative MCDA outcomes for positive HTA rec-
ommendations than the other way round. While MCDA
ratings were consistent with HTA outcomes regarding
the criteria used in processes such as clinical effective-
ness and safety considerations, it was the other aspects
that contributed most to a negative MCDA appraisal.
An interesting example of how additional criteria may
Table 2 The list of MCDA criteria
No. Main criterion Partial criteria together with corresponding weights
1. Indication uniqueness a) one unique indication (2 points),
b) more than one orphan indications (1 point),
c) one or more indications for common disease (0 points)
2. Disease rarity a) prevalence < 0,5 per 10,000 UE citizens (2 points),
b) prevalence in the range of 0,5 and 1 per 10,000 UE citizens (1 point),
c) prevalence >1 per 10,000 UE citizens (0 points)
3. Disease severity a) high mortality often with poor prognosis e.g. cancers (2 points)
b) chronic without high mortality and morbidity (1 point),
c) severe invalidity, severely harm of capacities central to individuals’ functioning in
society – e.g. hearing, eyesight etc. (1 point)
4. Advancement of technology a) Advanced therapy medicinal product (ATMP) including biopharmaceutical, innovative
synthetic entities and delivery systems as well non-biological complex drug (2 points),
b) conventional small molecule (molecular weight, MW < 500 Da) with at least one
stereogenic (chiral) center in its structure (1 point),
c) widely available simple chemical entities (e.g. zinc acetate) including molecules easily
synthesized from commercially available precursors - fine chemicals – (0 points)
5. Manufacturing technology complexity a) expensive biotechnological processes (2 points)
b) complex synthetic path consisting of at least three independent chemical
transformations (1 point)
c) manufacturing require the use of separation techniques for most intermediates (1 point)
6. Therapeutic alternative (unmet medical need) a) no comparable alternative available (2 points)
b) second line treatment available (1 point)
c) at least one comparable alternative available (0 points)
7. Scientific evidence for clinical efficiency
(level of uncertainty)
a) randomised placebo(or active)-controlled clinical trial(s) (RCT) with hard endpoints
such as overall survival or time to progression (TTP) (2 points),
b) randomised placebo(or active)-controlled clinical trial(s) (RCT) with surrogate endpoints
(1 points),
c) uncontrolled non-randomised clinical trial(s), observation studies or cohort studies with
relevant but only limited level of uncertainty (1 point),
d) very limited data with high level of uncertainty – e.g. case reports (0 points)
8. Benefits from use of medicine (safety and
adverse effects)
a) Only minor and reversible adverse events (2 points)
b) Low incidence of severe of adverse events (1 point)
c) High incidence of severe of adverse events (0 point)
9. Cost effectiveness a) ICER below 24 k€ (2 points)
b) ICER in the range between 24 k€ and 48 k€ (1 point)
c) ICER above 48 k€ (0 points)
10. Budget impact (in €) Total costs of reimbursement in first two years:
a) budget savings or positive budget impact below 1,2 M€ (2 points)
b) in the range between 1,2 and 2,4 M€ (1 point)
c) above 2,4 M€ (0 points)
Kolasa et al. Orphanet Journal of Rare Diseases  (2016) 11:23 Page 7 of 12
influence the P&R process could be the notion of the
availability of alternative therapy being introduced into
the MCDA tool. While the majority of cases above the
50 % threshold related to orphan drugs without a com-
parator, most drug-indication pairs scored below the
threshold concerned for rare conditions for which an
available treatment option exists. In the latter case, the
exception was Atriance, which was positively appraised
by AHTAPoL but gained a negative MCDA outcome. In
that particular case, the claim of a missing comparator is
questionable if one takes into consideration ‘trials of
various chemotherapeutic regimens based on individual
responses’ which may indicate the existence of some
alternative treatment options [23].
Looking into the potential impact of MCDA’s imple-
mentation into the P&R process, it is interesting to note
that the economic considerations tended to play a less
important role in MCDA appraisal compared to the
HTA process. An example in case could be Elapraze and
Fabrazyme. Both drugs were appraised negatively by
AHTAPoL but were scored the highest in the MCDA
appraisal process. On the one hand, the lack of a positive
HTA recommendation is not surprising if one takes into
account the fact that both products are positioned
amongst the world’s most expensive drugs [24]. On the
other hand, the multi criteria approach allowed eco-
nomic arguments against other characteristics of the
drug technologies in question to be balanced. Unless no
Table 3 MCDA outcomes for drug-indication pairs appraised by AHTAPol between 2007 and 2011 (economic criteria excluded)
















1 Elaprase 2 2 1 2 2 2 1 1 13
2 Fabrazyme 2 2 2 2 2 0 1 1 12
THRESHOLD 75 % 12 points
3 Nexavar (HCC) 1 2 2 0 2 2 2 0 11
4 Kuvan 0 2 1 1 2 2 1 2 11
5 Nplate 2 1 0 2 2 2 1 1 11
6 Cystadane 2 2 2 0 0 2 0 2 10
7 Yondelis 1 1 2 2 0 2 2 0 10
8 Somavert 2 1 1 2 2 0 1 1 10
9 Tasigna 2 2 2 0 0 2 1 1 10
10 Increlex 2 0 0 2 2 2 1 1 10
11 Glivec – (GIST) 0 2 2 0 1 2 2 0 9
12 Revlimid (MM/S) 1 0 2 1 0 2 2 1 9
13 Glivec (DFSP) 0 2 2 0 1 2 1 1 9
14 Torisel 1 0 2 2 2 0 1 1 9
15 Ventavis 2 0 1 1 2 0 1 1 8
16 Zavesca 1 1 2 1 0 0 1 2 8
17 Tracleer 1 1 1 0 2 0 1 2 8
18 Volibris 2 2 0 1 0 0 1 2 8
19/20 Nexavar (RCC) 1 0 2 0 2 1 2 0 8
THRESHOLD 50 % 8 points
21 Vidaza 1 0 2 1 0 0 2 1 7
22 Sprycel 1 1 2 0 0 1 1 1 7
23 Revlimid (MM) 1 0 2 1 0 0 2 1 7
24 Atriance 1 0 2 1 0 2 1 0 7
25 Glivec (ALL Ph+) 0 1 2 0 1 0 1 0 5
26 Revatio 0 1 1 0 0 0 1 2 5
27 Glivec (MDS/MPD) 0 0 2 0 1 0 1 0 4
THRESHOLD 25 % 4 points
Adv.tech. Advancement of technology, Sci. evid. clin.eff. scientific evidence for clinical efficiency, HCC Hepatocellular carcinoma, GIST Malignant gastrointestinal
stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma, ALL Ph+ Philadelphia
chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases
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differentiation across weights is applied, the adaptation
of a holistic approach may produce another hurdle for
payers concerned with budget impact. In this context it
could be mentioned that the economic considerations
did not influence the result of the MCDA appraisal to
any significant extent. With the 50 % threshold scenario,
there were only two changes of MCDA outcomes after
the economic criteria were included. While MCDA was
revised from negative to positive for Revlimid (MM), the
opposite occurred for Nexavar (RCC). At the same time,
affordability concerns were mentioned in as many as
66 % of negative HTA guidances.
Our study is not limitation free. Firstly, it has to be
acknowledged that subjectivity of the adaptation of the
MCDA tool might have introduced some bias into the
results. As far as the selection of criteria is concerned,
we deliberately excluded some of them to avoid ambigu-
ity. One exception was with respect to the ‘advancement
of technology’, which defines a product’s innovation in
terms of its active ingredients. The reason for its inclu-
sion is that it indirectly correlates with the level of
investment in R&D (research and development) and
manufacturing requirements [25]. As far as the appraisal
process is concerned, MCDA outcomes are based on the
subjective judgment of only two reviewers which could
have introduced some additional bias to the results. The
incorporation of more experts’ opinions could have
further improved the external validity of the MCDA
process. It certainly has to be taken into consideration
prior to any generalization of the results of our study.
Secondly, although some authors emphasize the im-
portant limitation of monetary criteria such as cost-
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THRESHOLD 75 % 15 points
1 Nexavar (HCC) 1 2 2 0 2 2 2 0 1 1 13
2 Nplate 2 1 0 2 2 2 1 1 1 1 13
3 Cystadane 2 2 2 0 0 2 0 2 0 2 12
4 Increlex 2 0 0 2 2 2 1 1 0 2 12
5 Revlimid
(MM/S)
1 0 2 1 0 2 2 1 1 2 12
6 Yondelis 1 1 2 2 0 2 2 0 1 0 11
7 Somavert 2 1 1 2 2 0 1 1 1 0 11
8 Tasigna 2 2 2 0 0 2 1 1 0 0 10
9 Torisel 1 0 2 2 2 0 1 1 0 1 10
THRESHOLD 50 % 10 points
10 Vidaza 1 0 2 1 0 0 2 1 1 0 8
11 Atriance 1 0 2 1 0 2 1 0 0 1 8
12 Nexavar (RCC) 1 0 2 0 2 1 2 0 0 0 8
THRESHOLD 25 % 5 points
Adv. tech. Advancement of technology, Sci. evid. clin. eff. scientific evidence for clinical efficiency, NA no data available, HCC Hepatocellular carcinoma, GIST Malignant
gastrointestinal stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma,
ALL Ph+ Philadelphia chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases
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effectiveness analysis, evaluation of economic data was
also performed [26]. This was not without challenges as
the full transparency of HTA reports published on the
AHTAPoL website was missing. This is especially true
with regard to the details of cost effectiveness and budget
impact analysis. In the majority of cases where economic
data were revealed, it was actually unfavorable budget
impact results that impacted MCDA to the greatest
extent. The appraisal might have led to different outcomes
if CEA and BIA results were available.
Finally, arbitrariness in the implementation of an
MCDA approach such as the choice of MCDA methods
and the lack of weighting of adopted criteria could have
biased the results as well. We chose a simple linear addi-
tive model because of its simplicity. It was believed to be
consistent with the way people usually made aggregation
as well. We do however have to acknowledge that there
are a number of drawbacks that might have impacted on
our results. As far as weights are concerned, we adopted
a very simple approach with a range from 0 to 2 points
per criterion irrespective of its importance. There is
some reason to believe that the process of assigning
weights should be based on discrete choice experiments
with the involvement of the representatives of society,
experts in the areas of health, as well as economists, and
finally patients and their caregivers [22]. Such weights
are very likely to be jurisdiction specific [22, 27]. For
example Mentzakis et al. performed discrete choice
experiments on a convenience sample of university
students in Canada to investigate individual preferences
regarding public funding for rare and common diseases
[28]. Surprisingly they found that the respondents did
not have a preference for the government to spend more
for drugs used to treat rare diseases.
Our contention is that an MCDA approach allows the
decision-making process to be structured under condi-
tions of better transparency and to support efforts for
more equitable distribution of healthcare public funds.
Even though our study does not provide evidence that
multi criteria analysis leads to a less restrictive decision
making process, we are cautious that the scarcity of
financial resources might trigger some resistance among
decision makers regarding the implementation of an
MCDA approach to the P&R processes for orphan drugs
in the CEE Region. The good news is that National
Health Fund spending for rare diseases has increased by
almost threefold in Poland since 2009 [29]. As long as
rare diseases are funded from the same budget as non-
orphan conditions, the decision makers may remain un-
willing to adopt different P&R rules for their evaluation.
Experiences from more developed countries indicate
that separate financing mechanisms may exist. For ex-
ample, a special fund called ‘AIFA 5 %’ was established
in Italy [30]. In England and Wales, drug technologies
for very rare diseases are currently assessed and commis-
sioned by NICE distinctly from other medicines used to
treat more common diseases [31]. In Scotland a special
fund dedicated to orphan medicinal products was set up
in 2013 as well [32]. In Australia some parts of very ex-
pensive drug technologies are reimbursed under a special
Life Saving Drug Program (LSDP) [33]. Drug technologies
qualify for LSDP if they are clinically necessary and effect-
ive, and cannot meet the cost-effectiveness criteria [33].
However, a separate financing mechanism does not
seem to be the only pre requisite condition for the suc-
cessful implementation of an MCDA approach. Aware-
ness of the need to adapt a wide range of P&R rules
with respect to the evaluation of orphan drugs has to be
raised as well. Input from experts is therefore required
to encourage dialogue between the general public and
the decision makers. Given the variation of social values
across jurisdictions, the list of criteria and their relative
weights requires incorporation of country specific pref-
erences. Hence it is unlikely that one standardized pan-
European set of rules could be successful. The efforts of
experts should therefore rather focus on the develop-
ment of a country specific MCDA framework instead.
Nevertheless an EU patient registry project could be of
great value in the pursuit of more equitable distribution
of healthcare resources for rare diseases as well. Not
only could such an endeavor help in collecting real life
data but also in handling uncertainty regarding clinical
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outcomes. It could be enormously beneficial to both de-
cision makers and patients when making their national
and individual decisions regarding treatment choices.
Conclusions
As our study revealed, an MCDA approach may lead to
different P&R outcomes compared to a standard HTA
process. On the one hand, enrichment of the list of deci-
sion making criteria leads to further scrutiny of the given
health technology and as such may increase the odds of
a negative P&R outcome. On the other hand, it uncovers
additional values and as such may increase the odds of
positive P&R outcomes.
In competition with common disease, where the in-
cremental gains are more significant, the pricing and
reimbursement decision making process for the treat-
ment of rare diseases will remain challenging. There is
a growing understanding that the allocation criteria
currently adopted, such as the cost effectiveness thresh-
old, does not allow the value of orphan drugs to be fully
captured [34]. It is therefore hoped that our study could
contribute to the discussion on the overall appropriate-
ness of the adaptation of an MCDA approach in CEE
settings and its usefulness in the search for more trans-
parent and equitable resource allocation in the health-
care sector.
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